Related Experiment Video

Updated: Mar 19, 2026

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

2.3K

Interaction of tRNA with MEK2 in pancreatic cancer cells

Xiaoyun Wang1, Christina R Chow2, Kazumi Ebine2

  • 1Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, IL 60637, USA.

Scientific Reports
|June 16, 2016
PubMed

Insights

Transfer RNA (tRNA) interacts with mitogen-activated protein kinase kinase 2 (MEK2) in pancreatic cancer cells. This tRNA-MEK2 interaction impacts MEK2

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Biochemistry

Background:

  • Transfer RNA (tRNA) is known for its translational role, but emerging evidence suggests additional functions.
  • Previous work identified mitogen-activated protein kinase kinase 2 (MEK2) as a protein interacting with tRNA.
  • The functional consequences of tRNA-protein interactions, particularly with MEK2, are not fully understood.

Purpose of the Study:

  • To investigate the consequences of the tRNA-MEK2 interaction in pancreatic cancer.
  • To evaluate the impact of disease and drug resistance-derived MEK2 mutants on this interaction.
  • To explore how tRNA influences MEK2 activity in the context of pancreatic cancer.

Main Methods:

  • Utilized pancreatic cancer cell lines to study tRNA-MEK2 interactions.
  • Generated and analyzed MEK2 mutants (Q60P, P128Q, S154F, E207K) associated with disease and drug resistance.
  • Employed the MEK2 inhibitor U0126 to assess its effect on the tRNA-MEK2 complex.

Main Results:

  • Confirmed tRNA interaction with both wild-type and mutant MEK2 in pancreatic cancer cells.
  • Demonstrated that the MEK2 inhibitor U0126 significantly reduces the tRNA-MEK2 interaction.
  • Observed that tRNA differentially affects the catalytic activity of wild-type and mutant MEK2 proteins.

Conclusions:

  • Established the interaction between tRNA and MEK2 in pancreatic cancer cells.
  • Provided evidence that tRNA influences MEK2 activity, suggesting a potential role in cancer progression.
  • Highlighted the significance of exploring non-canonical tRNA functions in disease contexts.

More Related Videos

Author Spotlight: Validating Cancer Therapy Responses with Desmoplastic Spheroid Models03:42

Author Spotlight: Validating Cancer Therapy Responses with Desmoplastic Spheroid Models

Published on: September 27, 2024

2.2K
An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

9.0K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.2K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.8K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.4K